Written by Lisa Phelps on August 3, 2017
Washington, D.C., August 3, 2017—The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, issued the following statement in response to the Senate passage of the Food and Drug Administration Reauthorization Act of 2017:
“Today the Senate joined the House in… Read More
Written by Jennifer Huron on April 5, 2017
Lawmakers are currently considering legislation to reauthorize FDA user fees. The FDA largely relies on user fees to operate and review innovative drugs, biologics, and devices. Not only does this legislation provide critical funding for FDA to quickly review products, but the user fee agreements also provide patients and… Read More
Written by Jennifer Huron on March 21, 2017
Washington, D.C., March 21, 2017—The National Organization for Rare Disorders (NORD) and Friends of Cancer Research, two leading organizations that collectively represent millions of Americans with cancer and rare diseases, issued the following statement in advance of this week’s… Read More
Written by Paul Melmeyer on February 3, 2014
The rare disease community has seen several policy wins in the past few months, some of which may have gone unnoticed. First, in November, Congress passed the National Pediatric Research Network Act as part of the PREEMIE Reauthorization Act. President Obama signed the measure into law on November 27th. … Read More
